Chelsea Therapeutics Reports Top-Line Results of Phase II Study of CH-4051

Chelsea Therapeutics announced that a preliminary analysis of its dose-ranging exploratory Phase II trial of CH-4051, a non-metabolized antifolate, in patients with rheumatoid arthritis or RA, who experience an inadequate response to methotrexate treatment indicates that CH-4051 did not demonstrate superior efficacy to methotrexate in the dose range evaluated.
NASDAQ